Coronavirus: AstraZeneca signs first COVID-19 vaccine supply deal with China

Published: Updated:
Read Mode
100% Font Size
2 min read

Shenzhen Kangtai Biological Products will produce AstraZeneca Plc's potential COVID-19 vaccine in mainland China, the British drugmaker said on Thursday, its first deal to supply one of the world's most populous countries.

To meet market demand in China, Shenzhen Kangtai will ensure it has annual production capacity of at least 100 million doses of the experimental shot AZD1222, which AstraZeneca co-developed with researchers at Oxford University, by the end of this year, AstraZeneca said.

Read more: Coronavirus: UAE to host world’s first Phase III clinical trials of COVID-19 vaccine

It must have capacity to produce at least 200 million doses by the end of next year as part of the exclusive framework agreement, its statement on the Chinese social media site WeChat added.

The two companies will also explore the possibility of cooperation on the vaccine candidate in other markets, AstraZeneca said.

For more coronavirus news, visit our dedicated page.

There are no approved vaccines for COVID-19, the highly contagious respiratory illness caused by the novel coronavirus, but the World Health Organization (WHO) has said AstraZeneca’s shot is one of the leading candidates.

The company has signed manufacturing deals globally to meet its target of making 2 billion doses of the vaccine.

The companies did not respond to requests for comment.

Read more:

COVID-19 vaccine: For smaller volume deals, Moderna will sell at $32-$37 per dose

Coronavirus: US authorities try to decide who’s first in line for COVID-19 vaccine

Coronavirus: Chinese-backed hackers targeted COVID-19 vaccine firm Moderna

Top Content Trending